Article and Video CATEGORIES
I had the opportunity to sit down with Dr. Matthew Horton, a pathologist who works with my own group at Swedish Cancer Institute in Seattle, at a pathology company called CellNetix. He did subspecialty training in lung pathology and is a terrific resource for my colleagues and me, and now for a wider audience.
The first part of our discussion focused on the major subtypes (called histologies) of NSCLC, including adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and the related large cell neuroendocrine carcinomas, along with a significant fraction of NSCLC tumors that can't be classified despite our efforts. So check out the links below for the audio and video versions of our discussion (the video with a few images of what we're talking about), and the associated transcript and figures.
dr-horton-intro-to-lc-path-nsclc-subtypes-audio-podcast
dr-horton-intro-to-lc-path-nsclc-subtypes-transcript
dr-horton-intro-to-lc-path-nsclc-subtypes-figures
In subsequent parts of this discussion, we'll cover the neuroendocrine family that ranges from carcinoids to small cell lung cancer and large cell neuroendocrine carcinomas, the different subtypes of adenocarcinomas, and other aspects of lung cancer pathology.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…